| 0 (0%) | 09-27 12:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 47.63 | 1-year : | 55.63 |
| Resists | First : | 40.77 | Second : | 47.63 |
| Pivot price | 39.13 |
|||
| Supports | First : | 37.96 | Second : | 36.22 |
| MAs | MA(5) : | 39.2 |
MA(20) : | 38.69 |
| MA(100) : | 40.87 |
MA(250) : | 36.93 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.5 |
D(3) : | 59.7 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 49.61 | Low : | 25.17 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EXEL ] has closed above bottom band by 47.0%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.29 - 39.51 | 39.51 - 39.71 |
| Low: | 38.09 - 38.38 | 38.38 - 38.65 |
| Close: | 38.62 - 39.04 | 39.04 - 39.43 |
Sat, 27 Sep 2025
Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook - MSN
Fri, 26 Sep 2025
Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50 - Yahoo Finance
Thu, 25 Sep 2025
Exel: Seo Kanghyeon will support global adoption of composite conductor cores - JEC - Connecting the World with Composites
Wed, 24 Sep 2025
Exelixis (EXEL) Valuation in Focus as New Adagene Partnership Expands Oncology Pipeline Potential - simplywall.st
Tue, 23 Sep 2025
EXEL Industries: Total number of voting rights and shares at 08.31.2025 - GlobeNewswire
Sun, 21 Sep 2025
The Bull Case For Exelixis (EXEL) Could Change Following Expanded Collaboration With Adagene’s SAFEbody Platform - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 269 (M) |
| Shares Float | 232 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 96.9 (%) |
| Shares Short | 17,630 (K) |
| Shares Short P.Month | 17,370 (K) |
| EPS | 2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.53 |
| Profit Margin | 27 % |
| Operating Margin | 37.5 % |
| Return on Assets (ttm) | 17.2 % |
| Return on Equity (ttm) | 29 % |
| Qtrly Rev. Growth | -10.9 % |
| Gross Profit (p.s.) | 7.98 |
| Sales Per Share | 8.28 |
| EBITDA (p.s.) | 2.9 |
| Qtrly Earnings Growth | -15.7 % |
| Operating Cash Flow | 772 (M) |
| Levered Free Cash Flow | 638 (M) |
| PE Ratio | 18.76 |
| PEG Ratio | 0 |
| Price to Book value | 5.18 |
| Price to Sales | 4.71 |
| Price to Cash Flow | 13.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|